BlueCrest Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlueCrest Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,018	Closed	-$530K	–	714
2019 Q2	$530K	Buy	22,018 +12,143	+123%	+$308K	0.04%	209
2019 Q1	$261K	Buy	+9,875	New	+$234K	0.01%	791
2018 Q3	–	Sell	-11,285	Closed	-$187K	–	1935
2018 Q2	$187K	Buy	+11,285	New	+$172K	﹤0.01%	1331
2018 Q1	–	Sell	-10,926	Closed	-$160K	–	1709
2017 Q4	$160K	Buy	+10,926	New	+$153K	﹤0.01%	731
2017 Q2	–	Sell	-42,300	Closed	-$625K	–	1194
2017 Q1	$625K	Sell	42,300 -4,000	-9%	-$64.8K	0.03%	399
2016 Q4	$749K	Sell	46,300 -3,258	-7%	-$59.1K	0.04%	413
2016 Q3	$898K	Buy	+49,558	New	+$968K	0.03%	402
2015 Q4	–	Sell	-69,796	Closed	-$1.38M	–	1270
2015 Q3	$1.38M	Buy	+69,796	New	+$2.21M	0.05%	363

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlueCrest Capital Management's HZNP Position: Q3 2019 in Review

BlueCrest Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 22,018 shares — an estimated $530K sold.

BlueCrest Capital Management first reported a position in HZNP in Q3 2015 and held it in 8 quarters. The position peaked at $1.38M in Q3 2015. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

BlueCrest Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
BlueCrest Capital Management sold 22,018 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $530K.
BlueCrest Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 8 quarters.
BlueCrest Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.38M in Q3 2015.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on BlueCrest Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.